FAB is a specialised Contract Research Organisation operating in monoclonal antibody engineering and production. H1’20 revenues grew circa 2.7 times to £1.75m vs a weak H1’19 (£0.66m) demonstrating a clear recovery and extending the strong H2’19 growth trend, up 15% (from £1.52m). FAB derived initial revenues from its newly launched RAMPTM technology and there was also a sustained reduction in net loss from £0.74m in H1’19 to £0.47m. This
05 Dec 2019
Meeting expectations: sustained growth in H1
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Meeting expectations: sustained growth in H1
Fusion Antibodies Plc (FAB:LON) | 3.8 0 (-1.3%) | Mkt Cap: 3.58m
- Published:
05 Dec 2019 -
Author:
Emma Ulker -
Pages:
3
FAB is a specialised Contract Research Organisation operating in monoclonal antibody engineering and production. H1’20 revenues grew circa 2.7 times to £1.75m vs a weak H1’19 (£0.66m) demonstrating a clear recovery and extending the strong H2’19 growth trend, up 15% (from £1.52m). FAB derived initial revenues from its newly launched RAMPTM technology and there was also a sustained reduction in net loss from £0.74m in H1’19 to £0.47m. This